This is a post-marketing observational clinical investigation conducted as part of the post-market clinical follow-up of ChitoCareĀ® Medical, aimed to confirm safety and efficacy according to the requirements of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, for the following indications: Gel - scars, conditions after dermatosurgical procedures, dermatitis, acne Spray - conditions after dermatosurgical procedures, dermatitis, acne
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Significant improvement in Vancouver Scar Scale (VSS)
Timeframe: 3 months
Significant improvement in Comprehensive Acne Severity Scale (CASS)
Timeframe: 2 months
Significant improvement in dermatitis severity scale
Timeframe: 2 months